跳至主要内容
临床试验/NCT04311099
NCT04311099已完成4 期

Laparoscopic vs Ultrasound-Guided Transversus Abdominis Plane Block in Minimally Invasive Colon Surgery: A Randomized Controlled Multicentre Clinical Trial

Claus Anders Bertelsen, PhD, MD5 个研究点 分布在 1 个国家目标入组 360 人开始时间: 2021年1月14日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
360
试验地点
5
主要终点
Total morphine dose equivalents administered.

研究概览

简要总结

The purpose of the trial is to identify the "most simple non-inferior of three different methods", placebo, laparoscopic assisted transverse abdominal plane block (L-TAP) and ultrasound guided TAP block (US-TAP), using postoperative opioid consumption as a measure of efficacy in patients undergoing elective minimally invasive colon surgery in an ERAS setting. Postoperative pain scores and length of stay (LOS) will also be measured. The simplicity of the three methods is ranked as: 1) placebo, 2) L-TAP and 3) US-TAP.

详细描述

Introducing laparoscopy in colorectal surgery and optimizing the postoperative care using the standardized protocols of enhanced recovery after surgery (ERAS) have significantly improved patient outcomes and LOS. Better pain management has the potential to further improve these outcomes. Since the introduction of ultrasound-guided abdominal wall blocks, much research has been done in that field, but no consensus has been reached concerning the optimal block technique; where to and when to inject the block, or which drug to use. Newly published randomized controlled trials show interesting results regarding the L-TAP which has several advantages to the US-TAP, including the ease of performance, less dependency on specialized skills or equipment and avoidance of intraperitoneal infiltration. but these results need to be solidified with multicentre trials. Besides optimizing postoperative pain management, better block techniques could potentially decrease LOS in patients after minimally invasive colorectal surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients planned to receive curative elective minimally invasive colon surgery for colon cancer or adenoma without a planned ostomy. Colon cancer or adenoma is defined by a distance of more than 15 cm from the anal verge to the distal limitation of the tumour or adenoma as measured by rigid sigmoidoscope. The following procedural codes are included:
  • Laparoscopic ileocecal resection
  • Laparoscopic right hemicolectomy
  • Other laparoscopic resection of both small and large bowel
  • Laparoscopic resection of transverse colon
  • Laparoscopic left hemicolectomy
  • Laparoscopic resection of sigmoid colon
  • Other laparoscopic colon resection
  • Having given informed written consent.

排除标准

  • Known allergy to local analgesics
  • Known liver failure Class C according to the Child-Pugh Score
  • Body weight of less than 40 kg
  • History of being a chronic pain patient (weekly intake WHO step II or step III or adjuvant step I analgesic)
  • Presence of concomitant painful conditions other than low back pain that could confound the subject's trial assessments or self-evaluation of the index pain, e.g., syndromes with widespread pain such as fibromyalgia
  • Predictably non-compliant due to language barrier or psychiatric disease
  • Patients rescheduled for open surgery, before the intervention has been administered
  • Patients where the indication for surgery changes before the intervention has been administered
  • Patients with known inflammatory bowel disease
  • Patients who have previously undergone open major abdominal surgery defined by prior intraabdominal surgery with a midline or upper abdominal incision of more than 8 cm
  • Incisional hernia
  • Patients with a history of abdominal wall surgery including resection of the external oblique muscles, the internal oblique muscles, the transversus abdominis muscles, the rectus abdominis muscles or their fascial components
  • Pregnancy (patients are screened using urine human chorionic gonadotropin upon admission if female and not postmenopausal).

研究组 & 干预措施

Ultrasound-guided TAP

Experimental

Ultrasound-guided TAP with 20 ml ropivacaine 2 mg/ml solution bilaterally and laparoscopic assisted injection of 20 ml saline (placebo) bilaterally at the beginning of surgery

干预措施: Active drug (Drug)

Ultrasound-guided TAP

Experimental

Ultrasound-guided TAP with 20 ml ropivacaine 2 mg/ml solution bilaterally and laparoscopic assisted injection of 20 ml saline (placebo) bilaterally at the beginning of surgery

干预措施: Placebo (Drug)

Ultrasound-guided TAP

Experimental

Ultrasound-guided TAP with 20 ml ropivacaine 2 mg/ml solution bilaterally and laparoscopic assisted injection of 20 ml saline (placebo) bilaterally at the beginning of surgery

干预措施: Injection of Ropivacaine - Ultrasound-guided transverse abdominal plane block (Procedure)

Ultrasound-guided TAP

Experimental

Ultrasound-guided TAP with 20 ml ropivacaine 2 mg/ml solution bilaterally and laparoscopic assisted injection of 20 ml saline (placebo) bilaterally at the beginning of surgery

干预措施: Injection of placebo - Laparoscopic assisted transverse abdominal plane block (Procedure)

Laparoscopic assisted TAP

Experimental

Laparoscopic assisted TAP with 20 ml ropivacaine 2 mg/ml solution bilaterally and ultrasound-guided injection of 20 ml saline (placebo) bilaterally at the beginning of surgery

干预措施: Active drug (Drug)

Laparoscopic assisted TAP

Experimental

Laparoscopic assisted TAP with 20 ml ropivacaine 2 mg/ml solution bilaterally and ultrasound-guided injection of 20 ml saline (placebo) bilaterally at the beginning of surgery

干预措施: Placebo (Drug)

Laparoscopic assisted TAP

Experimental

Laparoscopic assisted TAP with 20 ml ropivacaine 2 mg/ml solution bilaterally and ultrasound-guided injection of 20 ml saline (placebo) bilaterally at the beginning of surgery

干预措施: Injection of Ropivacaine - Laparoscopic assisted transverse abdominal plane block (Procedure)

Laparoscopic assisted TAP

Experimental

Laparoscopic assisted TAP with 20 ml ropivacaine 2 mg/ml solution bilaterally and ultrasound-guided injection of 20 ml saline (placebo) bilaterally at the beginning of surgery

干预措施: Injection of placebo - Ultrasound-guided transverse abdominal plane block (Procedure)

Placebo

Placebo Comparator

Laparoscopic assisted injection of 20 ml saline (placebo) bilaterally and ultrasound-guided injection of 20 ml saline (placebo) bilaterally at the beginning of surgery

干预措施: Placebo (Drug)

Placebo

Placebo Comparator

Laparoscopic assisted injection of 20 ml saline (placebo) bilaterally and ultrasound-guided injection of 20 ml saline (placebo) bilaterally at the beginning of surgery

干预措施: Injection of placebo - Ultrasound-guided transverse abdominal plane block (Procedure)

Placebo

Placebo Comparator

Laparoscopic assisted injection of 20 ml saline (placebo) bilaterally and ultrasound-guided injection of 20 ml saline (placebo) bilaterally at the beginning of surgery

干预措施: Injection of placebo - Laparoscopic assisted transverse abdominal plane block (Procedure)

结局指标

主要结局

Total morphine dose equivalents administered.

时间窗: The first 24 hours from the end of anesthesia.

Intravenously in milligrams.

次要结局

  • Total morphine dose equivalents administered in the operation theater.(Up to 12 hours.)
  • Postoperative pain when coughing - 8:00-10:00 AM Postoperative Day 1(Postoperative Day 1.)
  • Need for rescue TAP-block or epidural analgesia.(Postoperative Day 30.)
  • Total dose of antiemetic medication administered.(In the first 24 hours from the end of anesthesia.)
  • Total morphine dose equivalents administered in the post anesthesia care unit.(The first 24 hours from the end of anesthesia.)
  • Postoperative pain at rest - 8:00-10:00 AM (ante meridiem) Postoperative Day 1.(Postoperative Day 1.)
  • Postoperative length of stay.(Up to 30 days.)
  • Incidence of Postoperative Nausea and Vomiting - 8:00-10:00 AM Postoperative Day 1.(Postoperative Day 1.)
  • Quality of Recovery 15.(Postoperative Day 1.)
  • Total dose of antiemetic medication administered in the operating theater.(Up to 12 hours.)
  • Time spent in the post anesthesia care unit.(Up to 30 hours.)
  • Postoperative mobilisation.(Postoperative Day 1.)
  • Postoperative complications.(Postoperative Day 30.)

研究者

发起方
Claus Anders Bertelsen, PhD, MD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Claus Anders Bertelsen, PhD, MD

Associate professor, consultant surgeon

Nordsjaellands Hospital

研究点 (5)

Loading locations...

相似试验